Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Accounts Payables: 2021-2024

Historic Accounts Payables for ProQR Therapeutics N.V (PRQR) over the last 4 years, with Dec 2024 value amounting to $17.10.

  • ProQR Therapeutics N.V's Accounts Payables rose 947.33% to $356.56 in Q3 2025 from the same period last year, while for Sep 2025 it was $356.56, marking a year-over-year increase of 947.33%. This contributed to the annual value of $17.10 for FY2024, which is 98.97% down from last year.
  • As of FY2024, ProQR Therapeutics N.V's Accounts Payables stood at $17.10, which was down 98.97% from $1,667 recorded in FY2023.
  • ProQR Therapeutics N.V's 5-year Accounts Payables high stood at $399,937 for FY2022, and its period low was $17.10 during FY2024.
  • In the last 3 years, ProQR Therapeutics N.V's Accounts Payables had a median value of $1,667 in 2023 and averaged $133,874.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Accounts Payables skyrocketed by 76.94% in 2022, and later tumbled by 99.58% in 2023.
  • ProQR Therapeutics N.V's Accounts Payables (Yearly) stood at $226,029 in 2021, then soared by 76.94% to $399,937 in 2022, then tumbled by 99.58% to $1,667 in 2023, then slumped by 98.97% to $17.10 in 2024.